Traversing the valley of death: A guide to assessing prospects for translational success

Science Translational Medicine

Volumn 1, Issue 10, 2009, Pages

  Coller, Barry S ^a   Califf, Robert M ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRUG DESIGN; MEDICAL TECHNOLOGY; NATIONAL HEALTH ORGANIZATION; UNITED STATES;

DRUG DESIGN; NATIONAL INSTITUTES OF HEALTH (U.S.); TECHNOLOGY, MEDICAL; UNITED STATES;

EID: 77953920789     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000265     Document Type: Note

References (34)

1. R. M. Califf, L. Berglund, Linking scientifi c discovery and better health for the nation: The maturation of clinical and translational research in the United States. Acad. Med., in press.
2. J. L. Goldstein, M. S. Brown, The clinical investigator: Bewitched, bothered, and bewildered - but still beloved. J. Clin. Invest. 99, 2803-2812 (1997).
3. Congressional Budget Office Web site, Research and Development in the Pharmaceutical Industry. Available at http://www.cbo.gov/ftpdocs/76xx/doc7615/ 10-02-DrugR-D.pdf (accessed 16 September 2009).
4. A. J. Wood, A proposal for radical changes in the drug-approval process. N. Engl. J. Med. 355, 618-623 (2006).
5. U.S. Food and Drug Administration Web site, Critical Path Initiative Web page, Challenges and Opportunities Report-March 2004. Available at http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm (accessed 4 September 2009).
6. D. Butler, Translational research: Crossing the valley of death. Nature 453, 840-842 (2008).
7. D. G. Contopoulos-Ioannidis, G. A. Alexiou, T. C. Gouvias, J. P. Ioannidis, Medicine: Life cycle of translational research for medical interventions. Science 321, 1298-1299 (2008).
8. J. S. Stamler, R. L. Taber, R. M. Califf, Translation of academic discovery into societal benefit: Proposal for a balanced approach. Am. J. Med. 115, 596-599 and 683-688 (2003).
9. Clinical and Translational Science Awards Web site. Available at http://www.ctsaweb.org (accessed 4 September 2009).
10. A. R. Hayward, Making clinical research a robust career path. Acad. Med. 84, 409-410 (2009).
11. B. S. Coller, Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 92, 2373-2380 (1995).
12. W. F. Crowley, Jr., Translation of basic research into useful treatments: How often does it occur? Am. J. Med. 114, 503-505 (2003).
13. D. G. Contopoulos-Ioannidis, E. Ntzani, J. P. Ioannidis, Translation of highly promising basic science research into clinical applications. Am. J. Med. 114, 477-484 (2003).
14. E. M. Antman, E. Braunwald, A second look at bivalirudin. Am. Heart J. 142, 929-931 (2001).
15. M. Bala, C. N. Chin, A. T. Logan, T. Amin, L. J. Marnett, O. Boutaud, J. A. Oates, Acetylation of prostaglandin H2 synthases by aspirin is inhibited by redox cycling of the peroxidase. Biochem. Pharmacol. 75, 1472-1481 (2008).
16. P. J. Schlueter, R. T. Peterson, Systematizing serendipity for cardiovascular drug discovery. Circulation 120, 255-263 (2009).
17. The Lilly MDR-TB Partnership Web site. Available at http://www.lillymdr- tb.com (accessed 16 September 2009).
18. D. A. Chokshi, Improving access to medicines in poor countries: The role of universities. PLoS Med. 3, e136 http://www.plosmedicine.org/article/ info%3Adoi%2F10.1371%2Fjournal.pmed.0030136 (2006).
19. The Bill and Melinda Gates Foundation Web site. Available at http://www.gatesfoundation.org/ (accessed 16 September 2009).
20. William J. Clinton Foundation Web site. Available at http://www. clintonfoundation.org/ (accessed 16 September 2009).
21. E. Seoane-Vazquez, R. Rodriguez-Monguio, S. L. Szeinbach, J. Visaria, Incentives for orphan drug research and development in the United States. Orphanet J. Rare Dis. 3, 33 (2008).
22. NIH Web site, NIH Rapid Access to Interventional Development (NIH-RAID). Available at http://nihroadmap.nih.gov/raid/ (accessed 16 September 2009).
23. B. M. Kuehn, NIH program to boost pipeline for drugs to treat rare and neglected diseases. JAMA 302, 133-134 (2009).
24. U.S. Patent and Trademark Office Web site. Available at http://www.uspto.gov (accessed 14 September 2009).
25. S. A. Merrill, R. C. Levin, M. B. Myers, A Patent System for the 21st Century (National Academies Press, Washington, DC, 2004).
26. J. H. Barton, E. J. Emanuel, The patents-based pharmaceutical development process: Rationale, problems, and potential reforms. JAMA 294, 2075-2082 (2005).
27. J. A. DiMasi, H. G. Grabowski, Should the patent system for new medicines be abolished? Clin. Pharmacol. Ther. 82, 488-490 (2007).
28. P. Herrling, Patent sense. Nature 449, 174-175 (2007).
29. J. T. King Jr, J. Tsevat, J. R. Lave, M. S. Roberts, Willingness to pay for a quality-adjusted life year: Implications for societal health care resource allocation. Med. Decis. Making 25, 667-677 (2005).
30. M. R. Gold, J. E. Siegel, L. B. Russell, M. C. Weinstein, Eds., Cost-Effectiveness in Health and Medicine (Oxford Univ. Press, New York, 1996).
31. B. S. Coller, S. J. Shattil, The GPIIb/IIIa (integrin alphaIIb-beta3) odyssey: A technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112, 3011-3025 (2008).
32. D. J. Rader, Lecithin: Cholesterol acyltransferase and atherosclerosis: Another high-density lipoprotein story that doesn't quite follow the script. Circulation 120, 549-552 (2009).
33. R. M. Califf, D. L. DeMets, Principles from clinical trials relevant to clinical practice. Circulation 106, 1015-1021 and 1172-1175 (2002).
34. E. Marrer, F. Dieterle, Promises of biomarkers in drug development - a reality check. Chem. Biol. Drug Des. 69, 381-394 (2007).